8 May 2017

Holding(s) in Company

RNS Number : 5192E
Verona Pharma PLC
08 May 2017
 

 

 

 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
 

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to the
notification obligation:
 

Growth Equity Opportunities IV, LLC

4. Full name of shareholder(s)
 (if different from 3.):

 

5. Date of the transaction and date on
which the threshold is crossed or
reached:

May 2, 2017

6. Date on which issuer notified:

May 5, 2017

7. Threshold(s) that is/are crossed or
reached: 

8% to 9% change at direct interest level

         
 

 

8. Notified details:

A: Voting rights attached to shares 

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights 

Direct

Direct 

Indirect 

Direct

Indirect

Ordinary Shares

 

GB00B06GSH43

4,424,065

4,424,065

4,424,065

4,424,065

 

4.47%

 

 

US9250501064

 

 

5,333,328

5,333,328

 

5.39%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date 

Exercise/
Conversion Period 

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instrument

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date 

Exercise/
Conversion period 

Number of voting rights instrument refers to

 

% of voting rights 

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

9,757,393

9.86%

                                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: 

 

Growth Equity Opportunities IV, LLC is a limited liability company formed in the State of Delaware, United States

New Enterprise Associates 15, L.P., a limited partnership formed in the State of Delaware, is its sole member

NEA Partners 15, L.P., a limited partnership formed in the State of Delaware, is its general partner

NEA 15 GP, LLC, a limited liability company formed in the State of Delaware, is its general partner

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease
to hold:

 

12. Date on which proxy holder will cease to hold
voting rights:

 

 


13. Additional information:


Figures are based on a total number of 99,014,164 Ordinary Shares outstanding, as per the Company's Announcement of May 2, 2017.

14. Contact name:

Louis Citron, New Enterprise Associates

15. Contact telephone number:

+1 (410) 842-4000

     

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUBPAUPMGQR

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us